RecruitingNCT07354295
Integrating Multimodal AI to Predict Treatment Response and Refine Risk Stratification in Esophageal Cancer （Radiogenomics-Esophagus）
Multimodal AI-based Therapy Response Prediction and Risk Stratification for Esophageal Cancer
Sponsor
Shu Peng
Enrollment
1,500 participants
Start Date
Jul 26, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This AI-driven model leverages multimodal data-such as radiomics, pathomics, genomics, and broader multi-omics profiles-to capture complementary aspects of tumor biology and predict treatment response and prognosis.
Eligibility
Inclusion Criteria5
- Histopathologically diagnosed esophageal cancer
- Complete baseline clinical data available (including demographic characteristics, ECOG performance score, TNM staging, etc.)
- No other primary malignant tumors
- Provision of informed consent
- Availability of pre-treatment CT imaging
Exclusion Criteria3
- Imaging data quality insufficient for analysis
- Presence of another primary malignant tumor
- Severe systemic disease
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07354295
Related Trials
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
NCT051871821 location
Resilience and Equity in Aging, Cancer, and Health (REACH)
NCT046742671 location
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT0644597243 locations
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT0646994443 locations
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT0721770410 locations